Loading
Leads medical oncology at Tata Memorial and its programme of pragmatic trials that make treatments affordable.
Kumar Prabhash is Professor and Head of the Department of Medical Oncology at Tata Memorial Hospital, part of the Tata Memorial Centre in Mumbai. He leads the department's programme of pragmatic trials that make treatments affordable, including trials of oral metronomic chemotherapy in head and neck cancer, low-cost EGFR tyrosine kinase inhibitor strategies in lung cancer and low-dose immunotherapy studies. His publications include a trial comparing gefitinib alone with gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. His interests are head and neck cancer, lung cancer, metronomic chemotherapy and pragmatic trials.
| Title | Journal | Year |
|---|---|---|
| Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer | Journal of Clinical Oncology | 2020 |
| Low-dose immunotherapy in head and neck cancer: a randomised study (Tata Memorial) | Journal of Clinical Oncology | 2023 |
| MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer | New England Journal of Medicine | 2024 |
Patients newly diagnosed with EGFR-mutated advanced lung cancer now have a first-line option that improves survival over osimertinib, particularly if they have high-risk features. The trade-off is intravenous (now subcutaneous) infusions and considerably more skin, nail and clotting toxicity, so osimertinib alone remains reasonable for those who prioritise convenience and tolerability. Both this regimen and osimertinib plus chemotherapy (FLAURA2) are approved; there is no direct comparison.
For the majority of the world's head and neck cancer patients who cannot afford full-dose checkpoint inhibitors, a low dose added to oral metronomic chemotherapy is a tested alternative that improves survival. It also challenges the assumption that approved doses are the necessary doses: pharmacology had long suggested receptor saturation at far lower exposures.
Shares Low-dose immunotherapy in head and neck cancer: a randomised study (Tata Memorial), Confirm ultra-low-dose immunotherapy so it can be afforded where most patients live, Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial), Advanced Centre for Treatment, Research and Education in Cancer.
Shares Low-dose immunotherapy in head and neck cancer: a randomised study (Tata Memorial), Gefitinib vs gefitinib plus pemetrexed-carboplatin in EGFR-mutant lung cancer (Tata Memorial), Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial), Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial).
Shares Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Head and neck squamous cell carcinoma.
Shares MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer, EGFR, Non-small-cell lung cancer.
Shares Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial), Advanced Centre for Treatment, Research and Education in Cancer, Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial), Tata Memorial Centre.
Shares Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial), Tata Memorial Centre, Head and neck squamous cell carcinoma.
Shares Tata Memorial Centre, Head and neck squamous cell carcinoma.
Shares Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre.